- World Pharma News Home » Product » Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent
(a free service delivered by FeedBurner)
Bayer HealthCare and Onyx Pharmaceuticals, Inc. today announced that Nexavar® (sorafenib) tablets significantly improved overall survival by 47.3 percent (HR=0.68; p-value=0.014) in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC), or primary liver cancer, versus those receiving placebo. Nexavar also significantly improved time to progression in these patients by 74 percent (HR=0.57; P=0.001). These data will be presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) and further confirm Nexavar's efficacy in liver cancer.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments